+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

Linerixibat Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

Linerixibat Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
Setanaxib Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

Setanaxib Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
Seladelpar Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

Seladelpar Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
From
Cyclophilin Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cyclophilin Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Non-Structural Protein 5 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Non-Structural Protein 5 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Farnesoid X Receptor (FXR) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Farnesoid X Receptor (FXR) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
OXLUMO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

OXLUMO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • July 2023
  • 30 Pages
  • Global
From
Chronic Kidney Disease - Competitive landscape, 2023 - Product Thumbnail Image

Chronic Kidney Disease - Competitive landscape, 2023

  • Report
  • April 2023
  • 190 Pages
  • Global
From
Primary Sclerosing Cholangitis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Primary Sclerosing Cholangitis - Epidemiology Forecast - 2032

  • Report
  • August 2022
  • 91 Pages
  • Global
From
From
Hepatitis D - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hepatitis D - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Alcoholic Hepatitis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Alcoholic Hepatitis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Polycystic Kidney Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Polycystic Kidney Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more